Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Rheumatology

Understanding Your TRAPS Diagnosis

At a Glance

TRAPS is a rare inherited autoinflammatory disease caused by TNFRSF1A variants. A diagnosis helps guide flare treatment, genetic counseling, and regular blood and urine monitoring to reduce the risk of complications such as AA amyloidosis.

Receiving a diagnosis of Tumor Necrosis Factor Receptor 1 Associated Periodic Syndrome (TRAPS) often marks the end of a long and confusing journey. For many, this diagnosis is the first time their symptoms have been given a name after years of uncertainty. TRAPS is an autoinflammatory disease, a condition where the innate immune system—your body’s first line of defense—triggers intense inflammation without a typical external cause like a virus [1][2].

Because TRAPS is exceptionally rare, with some estimates suggesting it affects roughly 1 in 1 million people, many patients find they are the first person their local doctor has ever treated with the condition [3]. This rarity often leads to a significant diagnostic delay. On average, it takes between 5 and 16 years from the time symptoms first appear until a formal diagnosis is made [4][5]. During this time, it is common for patients to be misdiagnosed with more common conditions or for their symptoms to be dismissed.

How TRAPS Affects the Body’s Inflammatory Pathways

To understand TRAPS, it helps to know how the immune system normally signals danger. In a healthy body, a receptor called TNFR1 sits on the surface of your cells. When it detects a specific signaling molecule (TNF), it tells the cell to start an inflammatory response to protect the body.

In TRAPS, there is a mutation in the TNFRSF1A gene, which provides the instructions for building that TNFR1 receptor [6]. This mutation causes the receptor to function abnormally, leading to biological problems that depend on the specific variant:

  • Protein Misfolding and ER Stress: For certain severe (pathogenic) variants, the mutant receptor is “misshapen.” Instead of moving to the cell surface, these misfolded proteins get stuck inside a part of the cell called the endoplasmic reticulum (ER) [7][8]. This creates “ER stress” [6], causing the cell to pump out inflammatory signals inappropriately [9].
  • Other Pathways: Other variants (such as low-penetrance variants) may alter how the receptor is shed from the cell or affect other intracellular signaling pathways.

This inappropriate signaling is what causes the long-lasting fevers, muscle pain, and rashes characteristic of a TRAPS flare.

The Role of Genetics and Family Planning

TRAPS is a monogenic disease, meaning it is caused by a variation in a single gene [1]. It follows an autosomal dominant inheritance pattern. This means a person only needs to inherit one copy of the mutated gene from one parent to potentially develop the condition [10]. If you have a confirmed pathogenic variant, each biological child has a 50% chance of inheriting it.

However, not everyone with a TRAPS-related mutation will experience the same severity of symptoms.

  • Low-penetrance variants (such as the R92Q variant) often result in milder symptoms or shorter flares, and some people with these variants never develop symptoms at all [11].
  • High-penetrance variants typically cause more frequent and severe episodes [4].

Because interpreting genetics is complex, testing relatives should be guided by a genetic counselor who can explain informed consent and what the results actually mean for your family’s future [2].

Seeking Specialized Care

Because TRAPS is so rare and its biological mechanisms are complex, managing the condition usually requires a team of experts. Most patients benefit from seeing a rheumatologist or an immunologist who specializes in autoinflammatory diseases [2].

These specialists focus on two main goals:

  1. Controlling Flares: Using medications to quiet the immune response.
  2. Preventing Long-Term Damage: Monitoring for complications like AA amyloidosis, a condition where inflammatory proteins build up in organs like the kidneys [12][13].

Regular monitoring through blood tests (to check for markers like C-reactive protein or serum amyloid A) and urine tests is a standard part of long-term care to ensure the “intercritical” inflammation—the inflammation happening quietly between active flares—is being kept under control [2][14].

Common questions in this guide

What is TRAPS, and what causes it?
TRAPS is a rare autoinflammatory disease that causes repeated episodes of inflammation, often with prolonged fever, muscle pain, or rash. It is caused by a change in the TNFRSF1A gene, which affects the TNFR1 receptor and can activate inflammatory signals inappropriately.
Why can it take so long to diagnose TRAPS?
TRAPS is exceptionally rare, and its symptoms can resemble more common conditions. Because of this, people may be misdiagnosed or experience a long delay before the condition is recognized; reported diagnostic delays range from about 5 to 16 years.
How is TRAPS inherited, and could my children have it?
TRAPS usually follows an autosomal dominant inheritance pattern, meaning one altered gene copy can be enough to cause the condition. If you have a confirmed disease-causing TNFRSF1A variant, each biological child has a 50% chance of inheriting it, while a genetic counselor can explain what that means for your family.
What is the difference between high- and low-penetrance TRAPS variants?
High-penetrance variants are generally linked with more frequent and severe episodes. Low-penetrance variants, such as R92Q, may cause milder or shorter flares, and some people with these variants never develop symptoms.
Which specialists treat TRAPS?
A rheumatologist or immunologist with experience in autoinflammatory diseases can help manage TRAPS. A genetic counselor may also help interpret test results and discuss testing for relatives and family planning.
What monitoring is needed after a TRAPS diagnosis?
Regular blood tests, including C-reactive protein and serum amyloid A, help track inflammation during and between flares. Urine tests and kidney-function checks can help clinicians watch for organ effects and complications such as AA amyloidosis.
What is AA amyloidosis in TRAPS?
AA amyloidosis is a possible long-term complication in which inflammatory proteins build up in organs such as the kidneys. Keeping inflammation under control and following the recommended blood and urine monitoring plan can help your care team look for this complication.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific mutation was found in my TNFRSF1A gene, and is it considered a high-penetrance or low-penetrance variant?
  2. 2.How do my symptoms and labs (like CRP or serum amyloid A) compare to the typical presentation of TRAPS?
  3. 3.Given the rarity of TRAPS, is there a specialist or an autoinflammatory center of excellence you recommend for my ongoing care?
  4. 4.How often should we monitor my kidney function and serum amyloid A levels to check for long-term complications?
  5. 5.Should my family members or children be tested for this mutation, and can we meet with a genetic counselor to discuss the inheritance pattern?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Comparison of the clinical diagnostic criteria and the results of the next-generation sequence gene panel in patients with monogenic systemic autoinflammatory diseases.

    Sözeri B, Demir F, Sönmez HE, et al.

    Clinical rheumatology 2021; (40(6)):2327-2337 doi:10.1007/s10067-020-05492-8.

    PMID: 33165748
  2. 2

    The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist.

    Romano M, Arici ZS, Piskin D, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2022; (74(7)):1102-1121 doi:10.1002/art.42139.

    PMID: 35621220
  3. 3

    TNF Receptor-Associated Periodic Syndrome: An Analysis of a Slovakian Cohort of TRAPS Patients.

    Slenker B, Banovcin P, Hrubiskova K, et al.

    Archives of rheumatology 2025; (40(3)):288-298 doi:10.5152/ArchRheumatol.2025.11126.

    PMID: 41020641
  4. 4

    International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptor-Associated Periodic Syndrome, and Mevalonate Kinase Deficiency/Hyperimmunoglobulinemia D Syndrome.

    Ozen S, Kuemmerle-Deschner JB, Cimaz R, et al.

    Arthritis care & research 2017; (69(4)):578-586 doi:10.1002/acr.23120.

    PMID: 27723279
  5. 5

    Clinical and genetic features of Chinese adult patients with tumour necrosis factor receptor-associated periodic fever syndrome.

    Zhao M, Luo Y, Wu D, et al.

    Rheumatology (Oxford, England) 2020; (59(8)):1969-1974 doi:10.1093/rheumatology/kez569.

    PMID: 31774538
  6. 6

    A rare missense p.C125Y mutation in the TNFRSF1A gene identified in a Chinese family with tumor necrosis factor receptor-associated periodic fever syndrome.

    Qian M, Zhou J, Wu J, et al.

    Frontiers in genetics 2024; (15()):1413641 doi:10.3389/fgene.2024.1413641.

    PMID: 38978873
  7. 7

    The novel S59P mutation in the TNFRSF1A gene identified in an adult onset TNF receptor associated periodic syndrome (TRAPS) constitutively activates NF-κB pathway.

    Greco E, Aita A, Galozzi P, et al.

    Arthritis research & therapy 2015; (17()):93 doi:10.1186/s13075-015-0604-7.

    PMID: 25888769
  8. 8

    Functional analysis of a novel G87V TNFRSF1A mutation in patients with TNF receptor-associated periodic syndrome.

    Tsuji S, Matsuzaki H, Iseki M, et al.

    Clinical and experimental immunology 2019; (198(3)):416-429 doi:10.1111/cei.13365.

    PMID: 31429073
  9. 9

    Inositol-Requiring Enzyme 1-Mediated Downregulation of MicroRNA (miR)-146a and miR-155 in Primary Dermal Fibroblasts across Three TNFRSF1A Mutations Results in Hyperresponsiveness to Lipopolysaccharide.

    Harrison SR, Scambler T, Oubussad L, et al.

    Frontiers in immunology 2018; (9()):173 doi:10.3389/fimmu.2018.00173.

    PMID: 29467762
  10. 10

    Tumor necrosis factor receptor-associated cycle syndrome: a case report and literature review.

    Li Z, Jing X, Zhang S, et al.

    Frontiers in pediatrics 2023; (11()):1296487 doi:10.3389/fped.2023.1296487.

    PMID: 38155741
  11. 11

    Efficacy of anakinra in an adult patient with recurrent pericarditis and cardiac tamponade as initial manifestations of tumor necrosis factor receptor-associated periodic syndrome due to the R92Q TNFRSF1A variant.

    Camprubí D, Mitjavila F, Arostegui JI, Corbella X

    International journal of rheumatic diseases 2017; (20(4)):510-514 doi:10.1111/1756-185X.13029.

    PMID: 27990755
  12. 12

    Tumour necrosis factor receptor-1 associated periodic syndrome (TRAPS)-related AA amyloidosis: a national case series and systematic review.

    Delaleu J, Deshayes S, Rodrigues F, et al.

    Rheumatology (Oxford, England) 2021; (60(12)):5775-5784 doi:10.1093/rheumatology/keab252.

    PMID: 33715002
  13. 13

    Recurrent fever and arthralgia as the presentation of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in a Chinese girl: a case report and review of the literature.

    Chen Y, Huang X, Zheng S, et al.

    Clinical rheumatology 2018; (37(5)):1433-1438 doi:10.1007/s10067-018-4023-4.

    PMID: 29450850
  14. 14

    Use of the Auto-inflammatory Disease Activity Index to monitor disease activity in patients with colchicine-resistant Familial Mediterranean Fever, Mevalonate Kinase Deficiency, and TRAPS treated with canakinumab.

    Koné-Paut I, Piram M, Benseler S, et al.

    Joint bone spine 2022; (89(6)):105448 doi:10.1016/j.jbspin.2022.105448.

    PMID: 35944600

This page is for informational purposes only and does not constitute medical advice. Discuss your genetic results, symptoms, and monitoring plan with a rheumatologist, immunologist, or genetic counselor.

Get notified when new evidence is published on Tumor necrosis factor receptor 1 associated periodic syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.